Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomasz Bączek

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
Bioanalysis|December 9, 2014
Modern LC in therapeutic drug monitoring and diagnosis of pediatric leukemiaTomasz Bączek
Journal of Clinical Medicine|November 27, 2025
Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and ImatinibPiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|January 10, 2026
The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and AvapritinibPiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|March 14, 2026
Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab SoravtansinePiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|May 27, 2026
Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and AlpelisibPiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|June 26, 2026
Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and BelinostatPiotr Kawczak, Tomasz Bączek
Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents|October 18, 2011
Physicochemical interaction of antitumor acridinone derivatives with DNA in view of QSAR studiesMarcin Koba, Tomasz Bączek
Journal of Pharmaceutical and Biomedical Analysis|June 28, 2016
Non-invasive screening for neuroendocrine tumors-Biogenic amines as neoplasm biomarkers and the potential improvement of "gold standards"Natalia Miękus, Tomasz Bączek
Journal of Clinical Medicine|January 28, 2026
Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (<sup>177</sup>Lu)Vipivotide Tetraxetan, and AbirateronePiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|March 28, 2026
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and TucatinibPiotr Kawczak, Tomasz Bączek
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
Bioanalysis|December 9, 2014
Modern LC in therapeutic drug monitoring and diagnosis of pediatric leukemiaTomasz Bączek
Journal of Clinical Medicine|November 27, 2025
Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and ImatinibPiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|January 10, 2026
The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and AvapritinibPiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|March 14, 2026
Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab SoravtansinePiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|May 27, 2026
Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and AlpelisibPiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|June 26, 2026
Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and BelinostatPiotr Kawczak, Tomasz Bączek
Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents|October 18, 2011
Physicochemical interaction of antitumor acridinone derivatives with DNA in view of QSAR studiesMarcin Koba, Tomasz Bączek
Journal of Pharmaceutical and Biomedical Analysis|June 28, 2016
Non-invasive screening for neuroendocrine tumors-Biogenic amines as neoplasm biomarkers and the potential improvement of "gold standards"Natalia Miękus, Tomasz Bączek
Journal of Clinical Medicine|January 28, 2026
Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (<sup>177</sup>Lu)Vipivotide Tetraxetan, and AbirateronePiotr Kawczak, Tomasz Bączek
Journal of Clinical Medicine|March 28, 2026
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and TucatinibPiotr Kawczak, Tomasz Bączek
Pageof 19